Mason Carrico
Stock Analyst at Stephens & Co.
(3.74)
# 759
Out of 5,124 analysts
77
Total ratings
48.53%
Success rate
9.9%
Average return
Main Sectors:
Stocks Rated by Mason Carrico
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NTRA Natera | Maintains: Overweight | $197 → $235 | $229.09 | +2.58% | 6 | Nov 13, 2025 | |
| PACB Pacific Biosciences of California | Maintains: Overweight | $1.8 → $2 | $1.87 | +6.95% | 6 | Nov 10, 2025 | |
| HOLX Hologic | Downgrades: Equal-Weight | $78 → $76 | $74.49 | +2.03% | 6 | Oct 22, 2025 | |
| NEO NeoGenomics | Maintains: Overweight | $6.5 → $11 | $11.76 | -6.46% | 2 | Sep 2, 2025 | |
| VCEL Vericel | Reiterates: Overweight | $67 | $36.01 | +86.06% | 3 | Jun 16, 2025 | |
| ILMN Illumina | Reiterates: Overweight | $105 | $131.16 | -19.95% | 8 | May 20, 2025 | |
| TXG 10x Genomics | Reiterates: Overweight | $14 | $16.31 | -14.16% | 6 | May 15, 2025 | |
| CDNA CareDx | Reiterates: Overweight | $40 | $18.84 | +112.31% | 10 | May 5, 2025 | |
| GKOS Glaukos | Maintains: Overweight | $140 → $115 | $112.91 | +1.85% | 1 | May 2, 2025 | |
| VCYT Veracyte | Reiterates: Overweight | $45 | $42.10 | +6.89% | 7 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $55 | $102.14 | -46.15% | 5 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $5.05 | +18.81% | 2 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $17 | $23.09 | -26.38% | 2 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $52 | $72.80 | -28.57% | 2 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $20 | $6.15 | +225.20% | 4 | Jan 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $41 | $38.90 | +5.40% | 7 | Jan 2, 2025 |
Natera
Nov 13, 2025
Maintains: Overweight
Price Target: $197 → $235
Current: $229.09
Upside: +2.58%
Pacific Biosciences of California
Nov 10, 2025
Maintains: Overweight
Price Target: $1.8 → $2
Current: $1.87
Upside: +6.95%
Hologic
Oct 22, 2025
Downgrades: Equal-Weight
Price Target: $78 → $76
Current: $74.49
Upside: +2.03%
NeoGenomics
Sep 2, 2025
Maintains: Overweight
Price Target: $6.5 → $11
Current: $11.76
Upside: -6.46%
Vericel
Jun 16, 2025
Reiterates: Overweight
Price Target: $67
Current: $36.01
Upside: +86.06%
Illumina
May 20, 2025
Reiterates: Overweight
Price Target: $105
Current: $131.16
Upside: -19.95%
10x Genomics
May 15, 2025
Reiterates: Overweight
Price Target: $14
Current: $16.31
Upside: -14.16%
CareDx
May 5, 2025
Reiterates: Overweight
Price Target: $40
Current: $18.84
Upside: +112.31%
Glaukos
May 2, 2025
Maintains: Overweight
Price Target: $140 → $115
Current: $112.91
Upside: +1.85%
Veracyte
Mar 26, 2025
Reiterates: Overweight
Price Target: $45
Current: $42.10
Upside: +6.89%
Mar 26, 2025
Reiterates: Overweight
Price Target: $55
Current: $102.14
Upside: -46.15%
Mar 19, 2025
Reiterates: Overweight
Price Target: $6
Current: $5.05
Upside: +18.81%
Mar 18, 2025
Reiterates: Equal-Weight
Price Target: $17
Current: $23.09
Upside: -26.38%
Mar 6, 2025
Reiterates: Overweight
Price Target: $52
Current: $72.80
Upside: -28.57%
Jan 16, 2025
Reiterates: Equal-Weight
Price Target: $20
Current: $6.15
Upside: +225.20%
Jan 2, 2025
Reiterates: Overweight
Price Target: $41
Current: $38.90
Upside: +5.40%